FULL-TEXT ARTiCLE
Improved kidney function in patients who switch their protease
inhibitor from atazanavir or lopinavir to darunavir.
Jose S, Nelson M, Phillips A, ..et al
AIDS. 2017 Feb
20;31(4):485-492.
Paper
FULL-TEXT ARTICLE
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus
Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety
Outcomes in Clinical Practice.
Gantner P, Bani-Sadr F, Garraffo R, et
al
PLoS One. 2016 Oct
31;11(10):e0164240
Paper
Effects of a switch from tenofovir- to abacavir-based
antiretroviral therapy, with or without atazanavir, on renal
function.
Guillemi SA, Ling SH, Dahlby JS,
et al
J Int AIDS Soc. 2016 Sep
9;19(1):20995.
Abstract
Simplification to dual therapy (atazanavir/ritonavir + lamivudine)
versus standard triple therapy [atazanavir/ritonavir + two
nucleos(t)ides] in virologically stable patients on antiretroviral
therapy: 96 week results from an open-label, non-inferiority,
randomized clinical trial (SALT study).
Perez-Molina JA, Rubio R, Rivero A, et al
J Antimicrob Chemother. 2016
Sep 13.
Abstract
Low-dose versus standard-dose ritonavir-boosted
atazanavir in virologically suppressed Thai adults with HIV (LASA):
a randomised, open-label, non-inferiority trial.
Bunupuradah T, Kiertiburanakul S, Avihingsanon A, et al
Lancet HIV. 2016 Aug;3(8):e343-50.
Abstract
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir
vs Adding Atorvastatin in HIV-Infected Patients Receiving
Second-Line Antiretroviral Therapy With Hypercholesterolemia: A
Randomized Controlled Trial.
Wangpatharawanit P, Sungkanuparph S.
Clin Infect Dis.
2016 Jul 11
Abstract
Impact of switching from lopinavir/ritonavir to
boosted and un-boosted atazanavir on glucose metabolism: ATAzanavir
& GLUcose metabolism (ATAGLU) sudy.
d'Ettorre G, Ceccarelli G, Zaccarelli M, et al
Int J STD AIDS. 2015 Jun 10
Abstract
Immunological and Virological Outcomes of Patients
Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Akanmu AS, Adeyemo T, Lesi F, et al
Curr HIV Res.
2015;13(3):176-83.
Abstract
Long term effectiveness of once-daily unboosted
atazanavir plus abacavir/lamivudine as a switch strategy in subjects
with virological suppression.
Llibre JM, Cozzi-Lepri A, La Rosa JA, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19810.
Abstract
Unboosted atazanavir with lamivudine/emtricitabine
for patients with long-lasting virological suppression.
Carbone A, Galli L, Bigoloni A, et al
J Int AIDS Soc. 2014
Nov 2;17(4(Suppl 3)):19811.
Abstract
Boosted or unboosted atazanavir as a simplification of
lopinavir/ritonavir-containing regimens.
Castagna A, Galli L, Gianotti N,
et al
New Microbiol.
2013 Jul;36(3):239-49.
Abstract
ATV/r-based regimens: durable virological suppression
and good tolerability as switch strategy from NNRTI-containing
regimens in a real-life cohort.
Michalik C, Sönnerborg A, Jansen K,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18352.
Abstract
Switching to unboosted atazanavir combined with
tenofovir and emtricitabine is effective as maintenance therapy.
Maeland A,
Skeie L.
J Int AIDS Soc. 2012 Nov
11;15(6):18441
Abstract
Virological efficacy and safety of antiretroviral therapy-switch to
atazanavir-based regimen: a review of the literature.
Stephan C.
Expert Opin Pharmacother.
2012 Oct 10
Abstract
Switching to unboosted atazanavir reduces bilirubin and triglycerides without
compromising treatment efficacy i
n UGT1A1*28 polymorphism carriers.
Ferraris L, Viganò O, Peri A, et al
J Antimicrob Chemother.
2012 Jun 2.
Abstract |
ATZ
Journal Main Page
Home
Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
